BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 12057124)

  • 1. Chronic myelogenous leukemia in chronic phase.
    Kurzrock R; Kantarjian H; Talpaz M
    Curr Treat Options Oncol; 2001 Jun; 2(3):245-52. PubMed ID: 12057124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted chronic myeloid leukemia therapy: seeking a cure.
    Fausel C
    J Manag Care Pharm; 2007 Oct; 13(8 Suppl A):8-12. PubMed ID: 17970609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells.
    Topaly J; Zeller WJ; Fruehauf S
    Leukemia; 2001 Mar; 15(3):342-7. PubMed ID: 11237055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia].
    Buchdunger E
    Med Klin (Munich); 2002 Jan; 97 Suppl 1():2-6. PubMed ID: 11831067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted chronic myeloid leukemia therapy: Seeking a cure.
    Fausel C
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts.
    Sillaber C; Mayerhofer M; Agis H; Sagaster V; Mannhalter C; Sperr WR; Geissler K; Valent P
    Wien Klin Wochenschr; 2003 Aug; 115(13-14):485-504. PubMed ID: 13677268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Drug therapy of chronic myeloid leukemia].
    Hochhaus A; Berger U; Reiter A; Lahaye T; Kreil S; Hehlmann R
    Med Klin (Munich); 2002 Jan; 97 Suppl 1():7-15. PubMed ID: 11831070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor].
    Nakajima M; Toga W
    Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):482-90. PubMed ID: 14639002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
    Druker BJ; Talpaz M; Resta DJ; Peng B; Buchdunger E; Ford JM; Lydon NB; Kantarjian H; Capdeville R; Ohno-Jones S; Sawyers CL
    N Engl J Med; 2001 Apr; 344(14):1031-7. PubMed ID: 11287972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STI571: targeting BCR-ABL as therapy for CML.
    Mauro MJ; Druker BJ
    Oncologist; 2001; 6(3):233-8. PubMed ID: 11423669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STI571: a gene product-targeted therapy for leukemia.
    Mauro MJ; Druker BJ
    Curr Oncol Rep; 2001 May; 3(3):223-7. PubMed ID: 11296132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation.
    Olavarria E; Craddock C; Dazzi F; Marin D; Marktel S; Apperley JF; Goldman JM
    Blood; 2002 May; 99(10):3861-2. PubMed ID: 11986250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spotlight on imatinib mesylate in chronic myeloid leukemia.
    Curran MP; Croom KF; Goa KL
    BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.
    Scappini B; Onida F; Kantarjian HM; Dong L; Verstovsek S; Keating MJ; Beran M
    Cancer; 2002 May; 94(10):2653-62. PubMed ID: 12173333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics of BCR-ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction.
    Stentoft J; Pallisgaard N; Kjeldsen E; Holm MS; Nielsen JL; Hokland P
    Eur J Haematol; 2001; 67(5-6):302-8. PubMed ID: 11872078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571.
    Wolff NC; Ilaria RL
    Blood; 2001 Nov; 98(9):2808-16. PubMed ID: 11675355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of imatinib mesylate for hematopoietic stem cell transplantation.
    Goldman J
    Semin Hematol; 2001 Jul; 38(3 Suppl 8):28-34. PubMed ID: 11526599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
    Hochhaus A; Kreil S; Corbin AS; La Rosée P; Müller MC; Lahaye T; Hanfstein B; Schoch C; Cross NC; Berger U; Gschaidmeier H; Druker BJ; Hehlmann R
    Leukemia; 2002 Nov; 16(11):2190-6. PubMed ID: 12399961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
    Sawyers CL; Hochhaus A; Feldman E; Goldman JM; Miller CB; Ottmann OG; Schiffer CA; Talpaz M; Guilhot F; Deininger MW; Fischer T; O'Brien SG; Stone RM; Gambacorti-Passerini CB; Russell NH; Reiffers JJ; Shea TC; Chapuis B; Coutre S; Tura S; Morra E; Larson RA; Saven A; Peschel C; Gratwohl A; Mandelli F; Ben-Am M; Gathmann I; Capdeville R; Paquette RL; Druker BJ
    Blood; 2002 May; 99(10):3530-9. PubMed ID: 11986204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STI571 as a targeted therapy for CML.
    O'Dwyer ME; Mauro MJ; Druker BJ
    Cancer Invest; 2003 Jun; 21(3):429-38. PubMed ID: 12901289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.